



## 2023 Abstract Review Team Disclosures

The following types of relationships may be deemed relevant include:

1. Advisor or Review Panel Member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/Research Support
6. Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)
7. Independent Contractor
8. Ownership Interest
9. Royalties
10. Intellectual Property/Patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Other Financial or Material Support

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

*All of the relevant financial relationships listed for the meeting faculty have been mitigated.*

**Ablin, Jacob, MD**

Fibromyalgia and Other Clinical Pain Syndromes

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Abraham, David, PhD**

Systemic Sclerosis and Related Disorders: Basic Science Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Abril, Andy, MD**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Adamopoulos, Iannis, PhD**

Spondyloarthritis Including Psoriatic Arthritis: Basic Science Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Ahmed, Salahuddin, PhD, MSc**

Cytokines and Cell Trafficking Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Aizer, Juliet, MD, MPH**

Professional Education Category

Role: Abstract Reviewer

Disclosure: Pfizer, 5 (Terminated, August 31, 2022)

**Alarcón, Graciela, MD, MPH**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Al-Awqati, Mina, MD**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Alexanderson, Helene, PhD, PT**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Almeida de Jesus, Adriana, MD, PhD**

Genetics, Genomics, and Proteomics Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Anastasiou, Christine, MD**

Health Services Research Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Andreoli, Laura, MD, PhD**

Antiphospholipid Syndrome Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Angeles-Han, Sheila, MD, MSc**

Pediatric Rheumatology – Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Antiochos, Brendan, MD**

Vasculitis: Non-ANCA-Associated and Related Disorders Category  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose

**Antolini, Christopher, MD**

Rheumatoid Arthritis: Treatments Category  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose

**Appenzeller, Simone, MD, PhD**

Sjögren's Syndrome: Basic and Clinical Science Category  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose

**Aranow, Cynthia, MD**

Rheumatoid Arthritis: Treatments Category  
Role: Abstract Chair  
Disclosure: No relevant disclosure to display

**Ardoin, Stacy, MD, MSc**

Patient Outcomes, Preferences, and Attitudes Category  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose

**Aren, Kathleen, MPH, CHES**

ARP Research Methodology  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose

**Askanase, Anca, MD, MPH**

Systemic Lupus Erythematosus: Treatment Category  
Role: Abstract Reviewer  
Disclosure: Amgen, Data Safety Monitoring Board (Ongoing); AstraZeneca, 1 (Ongoing); Bristol-Myers Squibb(BMS), Clinical Trial Steering Committee (Ongoing); Genentech, Investigator in clinical trial (Ongoing); GlaxoSmithKlein(GSK), 1 (Ongoing); Idorsia, Lead PI for clinical trial (Ongoing); Sanofi, Lead PI clinical trial (Ongoing)

**Assassi, Shervin, MD, MS**

Genetics, Genomics, and Proteomics Category  
Role: Abstract Reviewer  
Disclosure: AstraZeneca, 2 (Ongoing); aTyr, 2 (Ongoing); Boehringer Ingelheim, 2 (Ongoing), 5 (Ongoing); CSL Behring, 2 (Ongoing); Janssen, 5 (Ongoing); Merck, 2 (Ongoing); Momenta, 5 (Ongoing); TeneoFour, 2 (Ongoing)

**Aydemir, Burcu, PhD**

ARP Psychology/Social Sciences  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose

**Aydin, Sibel, MD**

Imaging of Rheumatic Diseases Category

Role: Abstract Reviewer

Disclosure: abbvie, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); clarius, 11 (Ongoing); fresenius Kabi, 5 (Ongoing), 6 (Ongoing); Janssen, 5 (Ongoing), 6 (Ongoing); Pfizer, 5 (Ongoing), 6 (Ongoing); UCB, 5 (Ongoing), 6 (Ongoing)

**Bajaj, Puneet, MD, MPH**

Measures and Measurement of Healthcare Quality Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Baker, Matthew, MD, MS**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Reviewer

Disclosure: Beigene, 5 (Ongoing); Eli Lilly, 5 (Ongoing); Horizon Therapeutics, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Mobility Bio, 2 (Ongoing); Nēsos, 1 (Terminated, October 1, 2018), 2 (Terminated, October 1, 2018); Roivant, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Sanofi, 5 (Ongoing); Zenas Biopharma, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing)

**Baker, Joshua, MD, MS**

Imaging of Rheumatic Diseases Category

Role: Abstract Chair

Disclosure: CorEvitas, 2 (Ongoing); Cumberland Pharma, 2 (Terminated)

**Baldini, Chiara, MD, PhD**

Sjögren's Syndrome: Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: GlaxoSmithKlein(GSK), 6 (Ongoing); Horizon, 6 (Ongoing); Sanofi, 6 (Ongoing)

**Baraliakos, Xenofon, MD**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Reviewer

Disclosure: Abbvie, Amgen, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing)

**Barber, Megan, MD, PhD**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Barnas, Jennifer, MD, PhD, BS**

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Barrat, Franck, PhD**

Systemic Lupus Erythematosus: Etiology and Pathogenesis Category

Role: Abstract Reviewer

Disclosure: AstraZeneca, 2 (Ongoing); Boehringer-Ingelheim, 2 (Ongoing)

**Basiaga, Matthew, DO, MSCE**

Sjögren's Syndrome: Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Bass, Anne, MD**

Immunological Complications of Medical Therapy Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Baudek, Meggan, NP**

ARP Clinical Practice/Patient Care Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Beck, David, MD, PhD**

Genetics, Genomics, and Proteomics Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Bergman, Martin, MD**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Chair

Disclosure: AbbVie/Abbott, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Amgen, 2 (Ongoing); GlaxoSmithKlein(GSK), 6 (Ongoing); JNJ (Janssen), Shareholder (Ongoing); Merck/MSD, Shareholder (Ongoing); Pfizer, 2 (Ongoing); Regneron, 2 (Ongoing); Sanofi, 6 (Ongoing)

**Bermas, Bonnie, MD**

Reproductive Issues in Rheumatic Disorders Category

Role: Ad hoc Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Bernstein, Elana, MD, MSc**

Measures and Measurement of Healthcare Quality Category

Role: Abstract Chair

Disclosure: Boehringer-Ingelheim, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Kadmon, 5 (Ongoing); Pfizer, 5 (Ongoing)

**Binstadt, Bryce, MD, PhD**

Rheumatoid Arthritis: Animal Models Category

Role: Abstract Reviewer

Disclosure: Apollo Therapeutics, 5 (Ongoing)

**Bittar, Mohamad, MD, MS**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Blank, Rebecca, MD, PhD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Block, Joel, MD**

Orthopedics, Low Back Pain, and Rehabilitation Category

Role: Abstract Chair

Disclosure: EBSCO, 2 (Terminated, August 31, 2022); General Dynamics Information Technology, 1 (Terminated, October 31, 2022); GlaxoSmithKlein(GSK), 2 (Terminated, December 31, 2021); Navitas Clinical Research, Chair, DSMB (Ongoing); PK Med, 2 (Ongoing); Sanofi, 2 (Terminated, November 30, 2022)

**Bloom, Jessica, MD, MS**

Vasculitis: ANCA-Associated Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Bockenstedt, Linda, MD**

Innate Immunity Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Boin, Francesco, MD**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Chair

Disclosure: Boehringer-Ingelheim, 6 (Terminated, November 25, 2021); Janssen, 6 (Ongoing)

**Bottini, Nunzio**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Bujor, Andreea, MD, PhD**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Bulbin, David, DO, RhMSUS, FACR**

Imaging of Rheumatic Diseases Category

Role: Abstract Chair

Disclosure: AbbVie/Abbott, 2 (Ongoing), 6 (Ongoing); Alexion, 2 (Ongoing), 6 (Ongoing); Amgen, 2 (Ongoing), 6 (Ongoing); Novartis, 2 (Ongoing); Sanofi Genzyme, 6 (Ongoing)

**Buyon, Jill, MD**

Reproductive Issues in Rheumatic Disorders Category

Role: Ad hoc Reviewer

Disclosure: Bristol-Myers Squibb(BMS), 2 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); Related Sciences, 1 (Ongoing)

**Byram, Kevin, MD**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Caielli, Simone, PhD**

Systemic Lupus Erythematosus: Etiology and Pathogenesis Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Caricchio, Roberto, MD**

Systemic Lupus Erythematosus: Etiology and Pathogenesis Category

Role: Abstract Reviewer

Disclosure: AstraZeneca, 1 (Terminated); Cabaletta, 1 (Ongoing); GlaxoSmithKlein(GSK), 1 (Ongoing); Kyverna, 1 (Ongoing)

**Carvajal Bedoya, Guiset, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Case, Siobhan, MD, BA, MHS**

Health Services Research Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Castelino, Flavia, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Cavallo, Sabrina, PhD, OT**

ARP Pediatric Rheumatology

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Chan, Jonathan, MD, BSc, FRCPC**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Eli Lilly, 1 (Ongoing), 6 (Ongoing); Janssen, 1 (Ongoing), 6 (Ongoing); Novartis, 1 (Ongoing), 6 (Ongoing); UCB, 1 (Ongoing), 2 (Ongoing)

**Chang, Alison, MS, PT, DPT**

Osteoarthritis – Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Chang, Chih-Hao, PhD**

Systemic Lupus Erythematosus: Animal Models Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Charles, Julia, MD, PhD**

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing); Alexion, 2 (Ongoing); Novartis, 5 (Ongoing); Ultragenyx/Kirin, 2 (Ongoing)

**Chen, Yen, PhD**

ARP Psychology/Social Sciences

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Choi, Hyon K., MD, PhD**

Metabolic and Crystal Arthropathies – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: ANI, 1 (Ongoing); Horizon, 5 (Ongoing); LG Chem, 1 (Ongoing); Shanton, DSMB head (Ongoing)

**Choi, May, MD, FRCPC, MPH**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Chrostowski, Susan, APRN, DNP, ANP-C**

ARP Clinical Practice/Patient Care Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Chung, Lorinda, MD, MS**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Chair

Disclosure: Eicos Science, 1 (Ongoing), 2 (Ongoing); Eli Lilly, 1 (Ongoing), 2 (Ongoing); Genentech, 1 (Ongoing), 2 (Ongoing); IgM biosciences, 1 (Ongoing), 2 (Ongoing); Janssen, 1 (Ongoing), 2 (Ongoing); Kyverna, 1 (Ongoing), 2 (Ongoing); Mitsubishi Tanabe, 1 (Ongoing), 2 (Ongoing)

**Chung, Sharon, MD, MA**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Chung, Cecilia, MD, MPH**

Epidemiology and Public Health Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Clowse, Megan, MD, MPH**

Reproductive Issues in Rheumatic Disorders Category

Role: Abstract Chair

Disclosure: GlaxoSmithKlein(GSK), 2 (Ongoing), 5 (Ongoing); UCB, 2 (Ongoing), 5 (Ongoing)

**Colbert, Robert, MD, PhD**

Spondyloarthritis Including Psoriatic Arthritis: Basic Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose



**Collins, Kelsey, PhD**

Osteoarthritis & Joint Biology – Basic Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Corr, Maripat, MD**

Rheumatoid Arthritis: Animal Models Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Correll, Colleen, MD, MPH**

Pediatric Rheumatology – Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Corrigan, Patrick, PhD, DPT**

ARP Orthopedics, Low Back Pain and Rehabilitation

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Croft, Adam, PhD, MRCP**

Rheumatoid Arthritis: Etiology and Pathogenesis Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Cron, Randy, MD, PhD**

Pediatric Rheumatology – Basic Science Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 1 (Ongoing); Eli Lilly, 6 (Terminated); Pfizer, 1 (Ongoing); Sobi, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing)

**Cuda, Carla, PhD**

Systemic Lupus Erythematosus: Animal Models Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Cunningham, Melissa, MD, PhD**

Systemic Lupus Erythematosus: Etiology and Pathogenesis Category

Role: Abstract Chair

Disclosure: Aurinia, 1 (Terminated, May 30, 2023), 2 (Terminated, May 30, 2023)

**Curtis, Jeffrey, MD, MS, MPH**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Chair

Disclosure: AbbVie, 2 (Ongoing), 5 (Ongoing); Amgen, 2 (Ongoing), 5 (Ongoing); Bristol-Myers Squibb, 2 (Ongoing), 5 (Ongoing); CorEvitas, 2 (Ongoing), 5 (Ongoing); Eli Lilly and Company, 2 (Ongoing), 5 (Ongoing); Janssen, 2 (Ongoing), 5 (Ongoing); Myriad, 2 (Ongoing), 5 (Ongoing); Novartis, 2 (Ongoing), 5 (Ongoing); Pfizer, 2 (Ongoing), 5 (Ongoing); Sanofi, 2 (Ongoing), 5 (Ongoing); UCB, 2 (Ongoing), 5 (Ongoing)

**Cush, John, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing); Amgen, 2 (Ongoing); BMS, 2 (Ongoing); Novartis, 2 (Ongoing); UCB, 2 (Ongoing)

**Cutolo, Maurizio, MD**

Immunological Complications of Medical Therapy Category

Role: Abstract Reviewer

Disclosure: BI, 5 (Ongoing)

**Danila, Maria I. ("Maio"), MD, MSc, MPH**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Reviewer

Disclosure: RheumNow, Independent Contractor (Terminated)

**Davidson, Iris**

ARP Pediatric Rheumatology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Day, Jessica, PhD, MBBS, FRACP**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: CSL limited, 5 (Ongoing)

**De Bari, Cosimo, MD, PhD, FRCP**

Osteoarthritis & Joint Biology – Basic Science Category

Role: Abstract Reviewer

Disclosure: Biosplice, 5 (Ongoing); Galapagos, 2 (Ongoing), 6 (Ongoing); UCB, 2 (Terminated, March 9, 2021)

**de Vries-Bouwstra, Jeska, MD, PhD**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing), 6 (Ongoing); Boehringer-Ingelheim, 2 (Ongoing), 6 (Ongoing); galapagos, 5 (Ongoing); Janssen, 2 (Ongoing), 6 (Ongoing); Janssen-Cilag, 5 (Ongoing); Roche, 5 (Ongoing)

**Dellaripa, Paul, MD**

Muscle Biology, Myositis and Myopathies – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Delnay, Nancy, MSN, APRN**

ARP Pediatric Rheumatology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Demoruelle, Kristen, MD, PhD**

Rheumatoid Arthritis: Etiology and Pathogenesis Category

Role: Abstract Reviewer

Disclosure: Boehringer-Ingelheim, 5 (Ongoing); Gilead, 5 (Ongoing); Pfizer, 5 (Ongoing)

**Di Genaro, María Silvia, PhD**

Spondyloarthritis Including Psoriatic Arthritis: Basic Science Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**DiRenzo, Dana, MD, RhMSUS, MHS**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Distler, Oliver, MD**

Systemic Sclerosis and Related Disorders: Basic Science Category

Role: Abstract Chair

Disclosure: 4P Pharma, 2 (Ongoing); AbbVie/Abbott, 1 (Ongoing), 2 (Ongoing); Acceleron, 2 (Ongoing); AlciMed, 2 (Ongoing); Altavant, 2 (Ongoing); Amgen, 1 (Ongoing); AnaMar, 2 (Ongoing); Arxx, 2 (Ongoing); AstraZeneca, 2 (Ongoing); Blade, 2 (Ongoing); Boehringer-Ingelheim, 1 (Ongoing), 2 (Ongoing); Corbus, 2 (Ongoing); CSL Behring, 2 (Ongoing); Galapagos, 2 (Ongoing); Galderma, 2 (Ongoing); Glenmark, 2 (Ongoing); Gossamer, 2 (Ongoing); Kymera, 2 (Ongoing); Lupin, 2 (Ongoing); Medscape, 2 (Ongoing); Merck/MSD, 2 (Ongoing); Miltenyi Biotec, 2 (Ongoing); Mitsubishi Tanabe, 5 (Ongoing); Novartis, 1 (Ongoing), 2 (Ongoing); Prometheus, 2 (Ongoing); Redxpharma, 2 (Ongoing); Roivant, 2 (Ongoing); Topadur, 2 (Ongoing)

**Domsic, Robyn, MD, MPH**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Dowell, Sharon, MBBS, MSc**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Downey, Christina, MD, RhMSUS**

Miscellaneous Rheumatic and Inflammatory Diseases Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Dua, Anisha, MD, MPH**

Professional Education Category

Role: Abstract Chair

Disclosure: AbbVie/Abbott, 1 (Ongoing); chemocentryx, 1 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); Novartis, 1 (Ongoing); sanofi, 2 (Ongoing)

**Duarte-Garcia, Ali, MD, MSc**

Antiphospholipid Syndrome Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Dunlop-Thomas, Charmayne, MS, MPH**

ARP Psychology/Social Sciences

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Duryee, Michael, MS**

ARP Research Methodology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Eder, Lihi, MD, PhD**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Bristol-Myers Squibb(BMS), 2 (Terminated, April 12, 2023); Eli Lilly, 2 (Ongoing), 5 (Ongoing); Fresenius Kabi, 5 (Ongoing); Janssen, 2 (Ongoing), 5 (Ongoing); Novartis, 2 (Ongoing), 5 (Ongoing); Pfizer, 2 (Ongoing), 5 (Ongoing); UCB, 5 (Ongoing)

**Edwards, N. Lawrence, MD**

Metabolic and Crystal Arthropathies – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: Atom Biosciences, 2 (Ongoing); Horizon Pharmaceuticals, 2 (Ongoing); Shanton Pharmaceuticals, 2 (Ongoing)

**Ehrlich-Jones, Linda, RN, PhD**

ARP Psychology/Social Sciences

Role: Abstract Reviewer

Disclosure: Zimmer Biomet, 6 (Terminated, January 31, 2022)

**Elkon, Keith, MD**

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**England, Bryant, MD, PhD, RhMSUS**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Englund, Martin, MD, PhD**

Osteoarthritis – Clinical Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Erkan, Doruk, MD, MPH**

Antiphospholipid Syndrome Category

Role: Abstract Chair

Disclosure: ACR/EULAR, 5 (Ongoing); Aurinia, 6 (Ongoing); Exagen, 5 (Ongoing); GlaxoSmithKlein(GSK), 5 (Ongoing), 6 (Ongoing); Lupus Clinical Trials Consortium, 5 (Ongoing); NIH-NIAID, 5 (Ongoing); Up-To-Date, 9 (Ongoing)

**Ermann, Joerg, MD**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Reviewer

Disclosure: AbbVie, 2 (Terminated, September 30, 2021), 5 (Terminated, September 30, 2021); Eli Lilly, 2 (Ongoing); Janssen, 2 (Ongoing); Novartis, 2 (Ongoing), 5 (Ongoing); Pfizer, 2 (Terminated, December 31, 2022), 5 (Terminated, December 31, 2022); UCB, 2 (Ongoing)

**Eudy, Amanda, PhD**

ARP Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: Amgen, 2 (Ongoing); Exagen, 5 (Ongoing); GlaxoSmithKlein(GSK), 5 (Ongoing); Immunovant, 5 (Ongoing); Pfizer, 5 (Terminated, November 30, 2021)

**Falasinnu, Titilola, PhD**

Healthcare Disparities in Rheumatology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Farris, A. Darise, PhD**

Sjögren's Syndrome: Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Fearon, Ursula, PhD**

Rheumatoid Arthritis: Etiology and Pathogenesis Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Feely, Michael, MD**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Feghali-Bostwick, Carol, PhD**

Systemic Sclerosis and Related Disorders: Basic Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Feldman, Candace, MD, MPH, ScD**

Healthcare Disparities in Rheumatology

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Felson, David, MD, MPH**

ARP Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Ferguson, Polly, MD**

Innate Immunity Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Ferrada, Marcela, MD**

Infection-related Rheumatic Disease Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Fitzcharles, Mary-Ann, MD, FRCPC, MBChB**

Fibromyalgia and Other Clinical Pain Syndromes

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**FitzGerald, Oliver, MD**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Foeldvari, Ivan, MD**

Pediatric Rheumatology – Clinical Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Frie, Brenda, OT**

ARP Patient Education/Community Programs

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Garg, Shivani, MD, MS**

Healthcare Disparities in Rheumatology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**George, Michael, MD, MSc**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Chair

Disclosure: AbbVie/Abbott, 2 (Terminated, January 3, 2022); GlaxoSmithKlein(GSK), 5 (Ongoing); Janssen, 5 (Ongoing)

**Giles, Jon, MD, MPH**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Gizinski, Alison**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Gkrouzman, Elena, MD, MS, RhMSUS**

Antiphospholipid Syndrome Category

Role: Ad hoc Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Gladman, Dafna, MD, FRCPC**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Chair

Disclosure: Abbvie, 2 (Ongoing), 5 (Ongoing); Amgen, 2 (Ongoing), 5 (Ongoing); AstraZeneca, 2 (Ongoing); BMS, 2 (Ongoing); Eli Lilly, 2 (Ongoing), 5 (Ongoing); Janssen, 2 (Ongoing), 5 (Ongoing); Novartis, 2 (Ongoing), 5 (Ongoing); Pfizer, 2 (Ongoing), 5 (Ongoing); UCB, 2 (Ongoing), 5 (Ongoing)

**Glaser, Daniel, MD**

Pediatric Rheumatology – Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Gordon, Jessica, MD, MSc**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Gracey, Eric, PhD**

Spondyloarthritis Including Psoriatic Arthritis: Basic Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Gracia, Carol, APRN**

ARP Pediatric Rheumatology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Griffith, Melissa, MD, RhMSUS**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Chair

Disclosure: Gilead, 5 (Ongoing)

**Grom, Alexei, MD**

Pediatric Rheumatology – Basic Science Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Gross, Andrew, MD**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Grossman, Jennifer, MD**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Chair

Disclosure: ilumina, 11 (Ongoing); iqvia, 11 (Ongoing)

**Guma, Monica, MD, PhD**  
Cytokines and Cell Trafficking Category  
Role: Abstract Reviewer  
Disclosure: No relevant disclosure to display

**Haberman, Rebecca, MD**  
Infection-related Rheumatic Disease Category  
Role: Abstract Reviewer  
Disclosure: Janssen, 1 (Ongoing), 5 (Ongoing); UCB, 1 (Terminated, January 3, 2023)

**Hannan, Marian, DSc**  
ARP Epidemiology and Public Health Category  
Role: Abstract Reviewer  
Disclosure: Amgen, 5 (Terminated, December 1, 2022)

**Hant, Faye, DO**  
Systemic Sclerosis and Related Disorders: Clinical Category  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose

**Haroon, Nigil, MD, PhD, DM, FRCPC, FRCP, MBA**  
Innate Immunity Category  
Role: Abstract Reviewer  
Disclosure: No relevant disclosure to display

**Harris, Julia, MD**  
Infection-related Rheumatic Disease Category  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose

**Hazlewood, Glen, MD, PhD, FRCPC**  
Rheumatoid Arthritis: Diagnosis, Manifestions, and Outcomes Category  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose

**Helliwell, Philip, PhD, DM, FRCP, MA**  
Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category  
Role: Abstract Chair  
Disclosure: No relevant disclosure to display

**Hersh, Aimee, MD**  
Pediatric Rheumatology – Clinical Category  
Role: Abstract Chair  
Disclosure: No financial relationships with ineligible companies to disclose

**Hinze, Alicia, MD, MHS**  
Miscellaneous Rheumatic and Inflammatory Diseases Category  
Role: Abstract Reviewer  
Disclosure: No financial relationships with ineligible companies to disclose



**Hoi, Alberta, MD, PhD**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Holmqvist, Marie, PhD**

Muscle Biology, Myositis and Myopathies – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Hoover, Paul, MD, PhD**

Systemic Lupus Erythematosus: Animal Models Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Horomanski, Audra, MD, RhMSUS**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Horowitz, Diane, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Hsiao, Betty, MD**

Rheumatoid Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Hughell, Laurie, PA-C, MPH**

ARP Patient Education/Community Programs

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Humphrey, Mary Beth, MD, PhD**

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Hunter, David, PhD;MBBS;FRACP**

Osteoarthritis – Clinical Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Hwang, Mark, MD, MS**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Chair

Disclosure: Janssen, 5 (Ongoing); UCB Blopharma, 2 (Ongoing)

**Isenberg, David, MD, FRCP**

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Chair

Disclosure: Idorsia, 2 (Ongoing)

**Izmirly, Peter, MD**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Ad hoc Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Jackson, Lesley, MD**

Healthcare Disparities in Rheumatology

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Jafarzadeh, S. Reza, PhD**

ARP Epidemiology and Public Health Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Jamal, Shahin, MD, MSc**

Rheumatoid Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Joerns, Elena, MD**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Johnson, Tate, MD**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Jonas, Beth, MD**

Professional Education Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Jorge, April, MD**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Junek, Mats, MD, MSc**

Vasculitis: ANCA-Associated Category

Role: Abstract Reviewer

Disclosure: Roche, Educational support (Ongoing)

**Kahlenberg, J. Michelle, MD, PhD**

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Reviewer

Disclosure: Eli Lilly, 1 (Ongoing); Janssen, 5 (Ongoing)

**Kahn, Philip, MD**

Pediatric Rheumatology – Basic Science Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Kalunian, Kenneth, MD, FACR**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: Artiva Biosciences, 2 (Ongoing), 11 (Ongoing); Otsuka, 2 (Ongoing); RemeGen, 2 (Ongoing)

**Kamen, Diane, MD, MS**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Chair

Disclosure: Alpine Immune Sciences, 1 (Ongoing); Equillum, 1 (Ongoing)

**Karmacharya, Paras, MD, MS**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Chair

Disclosure: Janssen Scientific Affairs LLC, 5 (Ongoing)

**Karpoff, Marissa, MD**

Miscellaneous Rheumatic and Inflammatory Diseases Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Kasturi, Shanthini, MD, MS**

Measures and Measurement of Healthcare Quality Category

Role: Abstract Reviewer

Disclosure: GlaxoSmithKlein(GSK), 1 (Ongoing)

**Katz, Jeffrey, MD, MSc**

Orthopedics, Low Back Pain, and Rehabilitation Category

Role: Abstract Reviewer

Disclosure: Biosplice, 5 (Ongoing)

**Kavanaugh, Arthur, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: Eli Lilly, 2 (Ongoing)

**Kawai, Vivian, MD**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Keen, Helen, n/a**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Khanna, Puja, MD, MPH**

Healthcare Disparities in Rheumatology

Role: Abstract Chair

Disclosure: ArthroSi, 5 (Ongoing); Dyve, 5 (Ongoing); Horizon, 2 (Ongoing); Selecta, 5 (Ongoing)

**Khoja, Samannaaz, PhD, PT**

ARP Research Methodology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Khosroshahi, Arezou, MD**

Antiphospholipid Syndrome Category

Role: Ad hoc Reviewer

Disclosure: No relevant disclosure to display

**Kilian, Adam, MD**

Professional Education Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Kiltz, Uta, PhD**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Amgen, 6 (Ongoing); Bristol-Myers Squibb(BMS), 6 (Ongoing); Eli Lilly, 1 (Ongoing), 6 (Ongoing); Fresenius, 5 (Ongoing), 6 (Ongoing); GlaxoSmithKlein(GSK), 5 (Ongoing); Hexal, 5 (Terminated); Janssen, 1 (Ongoing), 6 (Ongoing); Merck/MSD, 6 (Ongoing); Novartis, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Pfizer, 6 (Ongoing); UCB, 1 (Ongoing), 6 (Ongoing)

**Kim, Alfred, MD, PhD**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Kim, Hanna, MD, MS**

Muscle Biology, Myositis and Myopathies – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: Eli Lilly and Company, CRADA (trial support including drug) (Ongoing)

**kishimoto, mitsumasa, MD**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: AbbVie, 1 (Ongoing), 6 (Ongoing); Asahikasei Pharma, 1 (Ongoing), 6 (Ongoing); Ayumi Pharma, 6 (Ongoing); BMS, 1 (Ongoing), 6 (Ongoing); Eisai, 1 (Ongoing), 6 (Ongoing); Eli Lilly, 1 (Ongoing), 6 (Ongoing); Gilead, 1 (Ongoing), 6 (Ongoing); Janssen, 1 (Ongoing), 6 (Ongoing); Novartis, 6 (Ongoing); Tanabe Pharma, 1 (Ongoing), 6 (Ongoing); UCB Japan, 6 (Ongoing)

**Kivitz, Alan, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 6 (Ongoing); Amgen, 6 (Ongoing), 11 (Ongoing); Chemocentryx, 4 (Ongoing); Eli Lilly, 6 (Ongoing); Fresenius Kabi, 2 (Ongoing); Genzyme, 2 (Ongoing), 11 (Ongoing); Gilead, 2 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing), 6 (Ongoing), 11 (Ongoing); Grunenthal, 2 (Ongoing); Horizon, 2 (Ongoing), 4 (Ongoing); Janssen, 2 (Ongoing), 4 (Ongoing); Novartis, 4 (Ongoing), 11 (Ongoing); Pfizer, 2 (Ongoing), 6 (Ongoing), 11 (Ongoing); Selecta, 2 (Ongoing); Takeda, 2 (Ongoing); UCB, 4 (Ongoing), 6 (Ongoing)

**Knight, Andrea, MD, MSCE**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Chair

Disclosure: Pfizer, 6 (Ongoing)

**Knight, Jason, MD, PhD**

Antiphospholipid Syndrome Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Ko, Kichul, MD**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Koenig, Curry, MD, MS**

Vasculitis: ANCA-Associated Category

Role: Abstract Chair

Disclosure: chemocentryx, 1 (Terminated, May 31, 2022), 6 (Terminated, May 31, 2022)

**Konig, Maximilian, MD**

Antiphospholipid Syndrome Category

Role: Abstract Chair

Disclosure: Argenx, 2 (Terminated); ManaT Bio, Intellectual Property/Patents (Ongoing); Revel Pharmaceuticals, 2 (Ongoing); Sanofi group, 2 (Terminated)

**Krause, Donnamarie, PhD, OT**

ARP Research Methodology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Kronzer, Vanessa, MD, MSc**

Rheumatoid Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Kuhn, Kristi, MD, PhD**

Rheumatoid Arthritis: Animal Models Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Kumar, Deepak, PhD, PT**

ARP Clinical Practice/Patient Care Category

Role: Abstract Reviewer

Disclosure: Eli Lilly, 5 (Ongoing); Pfizer, 5 (Ongoing)

**Kuriya, Bindee, MD, MS**

Rheumatoid Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Kuwana, Masataka, MD, PhD**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Reviewer

Disclosure: AsahiKasei, 6 (Ongoing); AstraZeneca, 4 (Ongoing); Boehringer-Ingelheim, 2 (Ongoing), 5 (Ongoing), 4 (Ongoing), 6 (Ongoing); Chugai, 2 (Ongoing), 6 (Ongoing); GlaxoSmithKlein(GSK), 4 (Ongoing); MBL, 9 (Ongoing); Ono Pharmaceuticals, 6 (Ongoing)

**Kyttaris, Vasileios, MD, PhD**

T-Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Lakin, Kimberly, MD, MS**

Infection-related Rheumatic Disease Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Lane, Nancy, MD**

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Category

Role: Abstract Chair

Disclosure: Amgen, 2 (Ongoing)

**Laufer, Terri, MD**

T-Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**LaValley, Michael, PhD**

ARP Research Methodology

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Le, Brian, MD**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Lebiedz-Odrobina, Dorota, MD, RhMSUS**

Fibromyalgia and Other Clinical Pain Syndromes

Role: Abstract Chair

Disclosure: Pfizer, Educational grant reviewer (Terminated)

**Lee, Jiha, MD, MS**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Legge, Alexandra, MD, FRCPC, MSc**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Leverenz, David, MD**

Professional Education Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Li, Linda, PhD, PT**

ARP Health Services Research

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Liang, Kimberly, MD, MS**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Lieber, Sarah, MD, MS**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Ad hoc Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Lieberman, Scott, MD, PhD**

Pediatric Rheumatology – Basic Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Liew, Jean, MD, MS**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Littlejohn, Geoffrey, MD, MBBS, FRACP, MPH**

Fibromyalgia and Other Clinical Pain Syndromes

Role: Abstract Reviewer

Disclosure: Astra Zeneca, 6 (Ongoing); Eli Lilly, 6 (Terminated, November 12, 2022)

**Littlejohn, Emily, DO, MPH**

Reproductive Issues in Rheumatic Disorders Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Loeser, Richard, MD**

Osteoarthritis – Clinical Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Lood, Christian, PhD**

Innate Immunity Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Loots, Gabriela**

Osteoarthritis & Joint Biology – Basic Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Lotz, Martin, MD**

Osteoarthritis & Joint Biology – Basic Science Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Lu, Theresa, MD, PhD**

Cytokines and Cell Trafficking Category

Role: Abstract Reviewer

Disclosure: Bristol-Myers Squibb(BMS), 6 (Terminated); Pfizer, 6 (Terminated)

**Luo, Yiming, MD, MHS**

Genetics, Genomics, and Proteomics Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Lydon, Eileen, NP, MA**

ARP Clinical Practice/Patient Care Category

Role: Abstract Reviewer

Disclosure: ALEXION, ADVISORY BOARD (Terminated); Amgen, ADVISORY BOARD (Terminated); aurinia, ADVISORY BOARD (Terminated); GlaxoSmithKlein(GSK), ADVISORY BOARD (Terminated); Novartis, ADVISORY BOARD (Terminated); ucb, ADVISORY BOARD (Ongoing)

**Müller-Ladner, Ulf, MD**

Immunological Complications of Medical Therapy Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 1 (Ongoing), 6 (Ongoing); Boehringer-Ingelheim, 1 (Ongoing), 6 (Ongoing); Galapagos, 1 (Ongoing), 6 (Ongoing); GSK, 1 (Ongoing), 6 (Ongoing); Janssen, 1 (Ongoing), 6 (Ongoing); Lilly, 1 (Ongoing), 6 (Ongoing); Medac, 1 (Ongoing), 6 (Ongoing); Novartis, 1 (Ongoing), 6 (Ongoing)

**Maccora, Ilaria, MD**

Pediatric Rheumatology – Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose



**Madsen, Norman, MBBS, FRCPC, RhMSUS, MSc, FACR**

Imaging of Rheumatic Diseases Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Magrey, Marina, MD**

Spondyloarthritis Including Psoriatic Arthritis: Basic Science Category

Role: Abstract Reviewer

Disclosure: Amgen, clinical trials (Ongoing)

**Makol, Ashima, MD**

Epidemiology and Public Health Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Makris, Una, MD, MSc**

Orthopedics, Low Back Pain, and Rehabilitation Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Maksimowicz-McKinnon, Kathleen, DO, MPH**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 1 (Terminated, December 30, 2022); Chemocentryx, 1 (Terminated, October 10, 2022)

**Malcarne, Vanessa, PhD**

ARP Psychology/Social Sciences

Role: Ad hoc Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Marder, Wendy**

Reproductive Issues in Rheumatic Disorders Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Massarotti, Elena, MD**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Master, Hiral, PhD, PT, MPH, MPT**

ARP Orthopedics, Low Back Pain and Rehabilitation

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Matsos, Mark, MD, FRCPC**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 6 (Ongoing); AstraZeneca, 6 (Ongoing); Bristol-Myers Squibb(BMS), 5 (Ongoing); GlaxoSmithKlein(GSK), 6 (Ongoing)

**McCoy, Sara, MD, PhD, RhMSUS**

Sjögren's Syndrome: Basic and Clinical Science Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**McMahan, Zsuzsanna, MD, MHS**

Systemic Sclerosis and Related Disorders: Basic Science Category

Role: Abstract Reviewer

Disclosure: Boehringer-Ingelheim, 2 (Ongoing)

**Meara, Alexa, MD, MS**

Immunological Complications of Medical Therapy Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing), 6 (Ongoing); Amgen, 2 (Ongoing), 6 (Ongoing); aurinia, 2 (Ongoing), 6 (Ongoing); awir, 1 (Ongoing); sanofi, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing)

**Mecoli, Christopher, MD**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Menzies, Victoria, PhD, APRN**

ARP Clinical Practice/Patient Care Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Merola, Joseph, MD, MSc**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing); Amgen, 2 (Ongoing); Biogen, 1 (Ongoing), 2 (Ongoing); Boehringer-Ingelheim, 2 (Ongoing); Bristol-Myers Squibb(BMS), 2 (Ongoing); Eli Lilly, 2 (Ongoing); Janssen, 2 (Ongoing), 5 (Ongoing); Novartis, 2 (Ongoing); UCB, 2 (Ongoing), 5 (Ongoing)

**Michailidou, Despina, MD**

Vasculitis: ANCA-Associated Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Mikuls, Ted, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Miller, Donald, PharmD, FASHP**

ARP Patient Education/Community Programs

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Miller, Karla, MD**

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Miller, Rachel, PhD, BS**

Osteoarthritis & Joint Biology – Basic Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Moore, Duncan, MD, RhMSUS**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Moroncini, Gianluca, MD, PhD**

Systemic Sclerosis and Related Disorders: Basic Science Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing), 6 (Ongoing); Boehringer-Ingelheim, 6 (Terminated); Janssen, 2 (Ongoing), 6 (Ongoing); Novartis, 6 (Ongoing); Pfizer, 2 (Ongoing), 6 (Ongoing)

**Mueller, Daniel, MD**

Rheumatoid Arthritis: Animal Models Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Mulcaire-Jones, Erica, MD**

Fibromyalgia and Other Clinical Pain Syndromes

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Muscal, Eyal, MD, MS**

Pediatric Rheumatology – Clinical Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Myasoedova, Elena, MD, PhD**

Epidemiology and Public Health Category

Role: Abstract Chair

Disclosure: Amgen, 1 (Terminated); Horizon Therapeutics, 1 (Terminated)

**Mysler, Eduardo, MD**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Nagaraja, Vivek, MD, FACR**

Measures and Measurement of Healthcare Quality Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Negron, Amarie, MD**

Fibromyalgia and Other Clinical Pain Syndromes

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Ng, Bernard, MBBS, MSc, MMed**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Nowell, William Benjamin, PhD, MSW**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 5 (Ongoing); Amgen, 5 (Ongoing); Janssen, 5 (Terminated, May 1, 2023); Scipher Medicine, 5 (Terminated, May 1, 2023)

**Nowling, Tammy, PhD**

Systemic Lupus Erythematosus: Animal Models Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Olenginski, Thomas, MD, FACP**

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**O'Neill, Sean, FRACP**

Systemic Lupus Erythematosus: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Onel, Karen, MD**

Pediatric Rheumatology – Basic Science Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Orbai, Ana-Maria, MD, MHS**

Measures and Measurement of Healthcare Quality Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 5 (Ongoing); Amgen, 5 (Terminated); Bristol-Myers Squibb(BMS), 2 (Terminated); Celgene, 5 (Terminated); Eli Lilly, 2 (Terminated), 5 (Terminated); Janssen, 2 (Ongoing), 5 (Ongoing); Novartis, 2 (Terminated), 5 (Terminated); Pfizer, 2 (Terminated)

**Ormseth, Michelle, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Østergaard, Mikkel, MD, PhD, DMSc**

Imaging of Rheumatic Diseases Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Amgen, 2 (Ongoing), 5 (Ongoing); Bristol-Myers Squibb(BMS), 5 (Terminated, May 23, 2023); Eli-Lilly, 2 (Ongoing), 6 (Ongoing); Janssen, 2

(Ongoing), 6 (Ongoing); MEDAC, 6 (Terminated, May 23, 2023); Novartis, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); UCB, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing)

**Overbury, Rebecca, MD**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Owen, Claire, PhD, MBBS**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 1 (Terminated, December 3, 2022), 6 (Terminated, December 3, 2022); Janssen, 6 (Terminated, May 5, 2023); Novartis, 6 (Terminated, February 4, 2023)

**Paik, Julie, MD, MHS**

Muscle Biology, Myositis and Myopathies – Basic and Clinical Science Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Park, Elizabeth, MD, MSc**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Patel, Aditi, MD**

Muscle Biology, Myositis and Myopathies – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Patrick, Anna, MD, PhD**

Pediatric Rheumatology – Basic Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Pauling, John, PhD, BSc, FRCP, MBBCH**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Chair

Disclosure: IsoMab, 1 (Ongoing), 2 (Ongoing)

**Pellegrini, Christine, PhD**

ARP Psychology/Social Sciences

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Perl, Andras, MD, PhD**

T-Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Perlman, Harris, PhD**

Rheumatoid Arthritis: Animal Models Category

Role: Abstract Chair

Disclosure: AnaptysBio, 2 (Ongoing)

**Perruccio, Anthony, PhD**

ARP Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Peschken, Christine, MD, FRCPC, MSc**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: AstraZeneca, 2 (Ongoing), 5 (Ongoing); GlaxoSmithKlein(GSK), 2 (Terminated, April 26, 2023); Roche, 1 (Ongoing)

**Peterkin-McCalman, Renee, MD, MPH**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Peterson, Erik, MD**

T-Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Petri, Michelle, MD, MPH**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Pillinger, Michael, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Chair

Disclosure: Federation Bio, 2 (Ongoing); Fortress Bioscience, 2 (Ongoing); Hikma Pharmaceuticals, 5 (Ongoing); Horizon Therapeutics, 2 (Ongoing), 5 (Ongoing); Sobi, 2 (Ongoing)

**Plotz, Benjamin, MD**

Metabolic and Crystal Arthropathies – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Pope, Richard, MD**

Cytokines and Cell Trafficking Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Prahalad, Sampath, MD, MSc**

Pediatric Rheumatology – Clinical Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Proft, Fabian, MD**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Amgen, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Bristol-Myers Squibb(BMS), 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Celgene, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Eli Lilly, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Janssen, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Merck/MSD, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Novartis, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); pfizer, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Roche, 2 (Ongoing), 6 (Ongoing); UCB, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing)

**Proudman, Susanna, MBBS**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Chair

Disclosure: Boehringer-Ingelheim, 1 (Ongoing), 5 (Ongoing), 6 (Ongoing); Janssen, 1 (Ongoing), 5 (Ongoing), 6 (Ongoing)

**Puravath, Abin, MD, FACP, MHS**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Putman, Mike, MD, MSc**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Quinn, Kaitlin, MD, MHS**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Rahimi, Homaira, MD, MS, FACR**

Rheumatoid Arthritis: Animal Models Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Rahman, Proton, MD**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Rathbun, Alan, PhD, MPH**

ARP Research Methodology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Raychaudhuri, Siba, MD**

Spondyloarthritis Including Psoriatic Arthritis: Basic Science Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Reddy, Soumya, MD**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Reid, Pankti, MD, MPH**

Professional Education Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Reveille, John**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Rhee, Rennie, MD, MS**

Vasculitis: ANCA-Associated Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Richez, Christophe, MD, PhD**

Systemic Lupus Erythematosus: Etiology and Pathogenesis Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing), 6 (Ongoing); Amgen, 6 (Terminated); Astra Zeneca, 2 (Ongoing), 6 (Ongoing); Biogen, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Celltrion, 2 (Ongoing); Galapagos, 6 (Terminated); GlaxoSmithKlein(GSK), 2 (Terminated), 6 (Terminated); Janssen, 6 (Terminated); Lilly, 5 (Ongoing), 6 (Ongoing); Merck/MSD, 6 (Ongoing); Novartis, 2 (Ongoing), 6 (Ongoing); Pfizer, 2 (Ongoing), 6 (Ongoing)

**Robinson, William, MD, PhD**

Rheumatoid Arthritis: Etiology and Pathogenesis Category

Role: Abstract Chair

Disclosure: Janssen, 5 (Ongoing); Sanofi, 5 (Ongoing)

**Rogers, Jennifer, MD**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Reviewer

Disclosure: Amgen, 2 (Terminated); Ampel Biosolutions, 1 (Terminated); Aurinia, 1 (Terminated); Eli Lilly, 1 (Terminated); Exagen, 5 (Ongoing); GlaxoSmithKlein(GSK), 2 (Terminated); Immunovant, 2 (Ongoing), 5 (Ongoing); Pfizer, 5 (Terminated)

**Rolle, Noelle A., MBBS**

Epidemiology and Public Health Category

Role: Abstract Chair

Disclosure: GlaxoSmithKlein(GSK), 2 (Ongoing)

**Rosenthal, Ann, MD**

Metabolic and Crystal Arthropathies – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose



**Ross, Laura, PhD, MBBS, FRACP**

Epidemiology and Public Health Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Rottmann, Eva, DO, RhMSUS**

Imaging of Rheumatic Diseases Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Roubey, Robert, MD**

Antiphospholipid Syndrome Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Ruderman, Eric, MD, FACP**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Chair

Disclosure: AbbVie/Abbott, 1 (Ongoing), 2 (Ongoing); Amgen, 2 (Ongoing); Aurinia, 2 (Terminated, August 31, 2022); Bristol-Myers Squibb(BMS), 2 (Ongoing); Eli Lilly, 2 (Ongoing); Janssen, 1 (Ongoing); Novartis, 2 (Ongoing); Pfizer, 2 (Ongoing), 5 (Ongoing); Selecta, 1 (Ongoing)

**Sadun, Rebecca, MD, PhD**

Infection-related Rheumatic Disease Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Saketkoo, Lesley Ann, MD, MPH**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Chair

Disclosure: Argenx Pharmaceuticals, 1 (Ongoing), 2 (Ongoing); aTyr Pharmaceuticals, 2 (Ongoing), 5 (Ongoing); Boehringer-Ingelheim, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Corbus Pharmaceuticals, 1 (Ongoing), 5 (Ongoing); Horizon Pharmaceuticals, 5 (Ongoing); Janssen, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Kadmon Pharmaceuticals, 5 (Ongoing); Kinevant Pharmaceuticals, 5 (Ongoing)

**Sammaritano, Lisa, MD**

Reproductive Issues in Rheumatic Disorders Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Sampson, Laura, PA-C**

ARP Patient Education/Community Programs

Role: Abstract Reviewer

Disclosure: Eli Lilly, 1 (Terminated, January 31, 2023)

**Samuels, Jonathan, MD, RhMSUS**

Osteoarthritis – Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Sandorfi, Nora, MD**

Miscellaneous Rheumatic and Inflammatory Diseases Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Satterthwaite, Anne, PhD**

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Reviewer

Disclosure: Amgen, 11 (Ongoing)

**Sattui, Sebastian, MD, MS**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Sawalha, Amr, MD**

Genetics, Genomics, and Proteomics Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Saxena, Amit, MD**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 1 (Terminated, March 15, 2023); AstraZeneca, 1 (Ongoing); GlaxoSmithKlein(GSK), 1 (Terminated, December 8, 2021)

**Saygin, Didem, MD**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Scanzello, Carla, MD, PhD**

Osteoarthritis & Joint Biology – Basic Science Category

Role: Abstract Chair

Disclosure: N/A, Intellectual Property/Patents (Ongoing)

**Scher, Jose, MD**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Schett, Georg, MD**

Rheumatoid Arthritis: Etiology and Pathogenesis Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Schlesinger, Naomi, MD**

Metabolic and Crystal Arthropathies – Basic and Clinical Science Category

Role: Abstract Chair

Disclosure: ANI, 1 (Terminated); Arthosi, 1 (Ongoing); Horizon, 1 (Ongoing); Novartis, 1 (Ongoing); Olatec, 1 (Ongoing), 5 (Ongoing); Protalix, 1 (Ongoing); Shanton, 1 (Ongoing); SOBI, 1 (Terminated)

**Schmajuk, Gabriela, MD, MS**

Measures and Measurement of Healthcare Quality Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Schulert, Grant, MD, PhD**

Pediatric Rheumatology – Clinical Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Schwarz, Edward, PhD**

Cytokines and Cell Trafficking Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Shadick, Nancy, MD, MPH**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Reviewer

Disclosure: Abbvie, 5 (Ongoing); AQtual, 5 (Ongoing); Bristol-Myers Squibb(BMS), 5 (Ongoing); Janssen, 5 (Ongoing)

**Shah, Ankoor, MD**

Epidemiology and Public Health Category

Role: Abstract Chair

Disclosure: Boehringer-Ingelheim, 5 (Ongoing), 6 (Ongoing); Horizon, 5 (Ongoing)

**Shahane, Anupama**

Miscellaneous Rheumatic and Inflammatory Diseases Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Shahrara, Shiva, PhD**

Cytokines and Cell Trafficking Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Shakoor, Najia, MD**

Osteoarthritis – Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Siegel, Evan, MD**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 2 (Ongoing), 6 (Ongoing); Bristol-Myers Squibb(BMS), 2 (Ongoing); Horizon, 6 (Ongoing); Janssen, 2 (Ongoing), 6 (Ongoing); Novartis, 2 (Ongoing); UCB, 2 (Ongoing), 6 (Ongoing)

**Simard, Julia, MSc, ScD**

Reproductive Issues in Rheumatic Disorders Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Simonini, Gabriele, MD**

Pediatric Rheumatology – Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Simpfendorfer, Kim, PhD**

Genetics, Genomics, and Proteomics Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Sims, Catherine, MD**

Reproductive Issues in Rheumatic Disorders Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Singh, Namrata, MD, MSc**

Rheumatoid Arthritis: Diagnosis, Manifestations, and Outcomes Category

Role: Abstract Reviewer

Disclosure: Pfizer, 1 (Terminated, April 29, 2022)

**Sivaraman, Vidya, MD**

Pediatric Rheumatology – Clinical Category

Role: Abstract Reviewer

Disclosure: CVS, 11 (Ongoing); Merck, 11 (Ongoing)

**Skaug, Brian, MD, PhD**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Skopelja-Gardner, Sladjana, PhD**

Systemic Lupus Erythematosus: Animal Models Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Smarr, Karen, PhD**

ARP Psychology/Social Sciences

Role: Ad hoc Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Smith, Vanessa, MD, PhD, -None-**

Immunological Complications of Medical Therapy Category

Role: Abstract Chair

Disclosure: Argenx, 2 (Terminated); Boehringer-Ingelheim, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Galapagos, 6 (Terminated); Janssen, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); WebMD Global LLC, 2 (Terminated)

**Smith, Chelsey, MD**

Rheumatoid Arthritis: Treatments Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Smith, Judith, MD, PhD**

Innate Immunity Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Smitherman, Emily, MD, MS**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Snow, Marcus, MD**

Miscellaneous Rheumatic and Inflammatory Diseases Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Soriano, Enrique, MD, MSc**

Spondyloarthritis Including Psoriatic Arthritis: Treatment Category

Role: Abstract Reviewer

Disclosure: Abbvie, 1 (Ongoing), 5 (Ongoing), 6 (Ongoing); Amgen, 5 (Terminated, May 18, 2023), 6 (Terminated, May 18, 2023); GlaxoSmithKlein(GSK), 1 (Ongoing), 6 (Ongoing); Janssen, 1 (Ongoing), 5 (Ongoing), 6 (Ongoing); Novartis, 1 (Ongoing), 5 (Ongoing), 6 (Ongoing); Pfizer, 5 (Ongoing), 6 (Ongoing); UCB, 6 (Ongoing)

**Stamatos, Christine, DNP, ANP-C**

ARP Clinical Practice/Patient Care Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Steinbarger, Kimberly, PT, MHS, DHSc**

ARP Patient Education/Community Programs

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Stern, Sara, MD**

Sjögren's Syndrome: Basic and Clinical Science Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Stoll, Matthew, MD, PhD, MSCS**

Innate Immunity Category

Role: Abstract Chair

Disclosure: Novartis, 2 (Ongoing)

**Strand, Vibeke, MD, FACP, MACR**

Immunological Complications of Medical Therapy Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Sun, Kai, MD, MS, RhMSUS**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Tesser, John, MD, FACP, FACP**

Rheumatoid Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: AbbVie/Abbott, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Acelyrin, 5 (Ongoing); Alpine, 5 (Ongoing); Amgen, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Anthrosi Therapeutics, 5 (Ongoing); Aurinia, 1 (Ongoing), 5 (Ongoing), 6 (Ongoing); Bencare, 5 (Ongoing); Biogen, 5 (Ongoing); Biosplice, 2 (Ongoing), 5 (Ongoing); Boehringer-Ingelheim, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Bristol-Myers Squibb(BMS), 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Corevitas, 5 (Ongoing); CSL Behring, 5 (Ongoing); DRL, 5 (Ongoing); Eli Lilly, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Emerald, 5 (Ongoing); Exagen, 5 (Terminated); Genentech, 5 (Ongoing), 6 (Ongoing); Gilead, 5 (Ongoing); GlaxoSmithKlein(GSK), 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Global Health Living Foundation, 5 (Ongoing); Horizon, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Janssen, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Kolon TissueGene, 5 (Ongoing); Mitsubishi, 5 (Ongoing), 5 (Ongoing); Nesos, 5 (Terminated); Novartis, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Organogenesis, 5 (Ongoing); Pfizer, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Sanofi-Genzyme, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Selecta, 5 (Ongoing); Setpoint, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Shanton, 5 (Ongoing); Sun Pharma, 5 (Ongoing); Takeda, 5 (Ongoing); UCB, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Ventyx Biosciences, 5 (Ongoing)

**Thoma, Louise, PhD, DPT**

ARP Health Services Research

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Thomas, Julie, MD**

Healthcare Disparities in Rheumatology

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Tilstra, Jeremy, MD, PhD**

Systemic Lupus Erythematosus: Animal Models Category

Role: Abstract Reviewer

Disclosure: Mitsubishi Tanabe Pharma Corporation, 5 (Terminated, April 1, 2023)

**Tiwari, Vivekanand, MBBS**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Tolaymat, Omar, MD, RhMSUS**

Vasculitis: Non-ANCA-Associated and Related Disorders Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Tomasson, Gunnar, MD**

Vasculitis: ANCA-Associated Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Toprover, Michael, MD**

Metabolic and Crystal Arthropathies – Basic and Clinical Science Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Torok, Kathryn, MD**

Pediatric Rheumatology – Clinical Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Touma, Zahi, MD, PhD**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Trotter, Kimberly, MD**

Systemic Lupus Erythematosus: Treatment Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Tsaltskan, Vlad, MD**

Rheumatoid Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Ugarte-Gil, Manuel, MD, MSc**

Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: AstraZeneca, 1 (Terminated), 6 (Terminated); GlaxoSmithKlein(GSK), 6 (Terminated); Janssen, 5 (Ongoing)

**Umer, Sarwat, MD**

ARP Patient Education/Community Programs

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Valenzuela, Antonia, MD, MS**

Systemic Sclerosis and Related Disorders: Clinical Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Vukelic, Milena, MD**

T-Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Wallace, Beth, MD, MS**

Rheumatoid Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Waterfield, Michael, MD, PhD**

Systemic Lupus Erythematosus: Etiology and Pathogenesis Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Wei, Kevin, MD, PhD**

Rheumatoid Arthritis: Etiology and Pathogenesis Category

Role: Abstract Reviewer

Disclosure: 10X Genomics, 5 (Ongoing), instruments and reagents (Ongoing); Horizons therapeutics, 6 (Ongoing)

**Weinstein, Jason, PhD**

T-Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Weiss, Pamela, MD**

Spondyloarthritis Including Psoriatic Arthritis: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Welin, Elisabet, RN, PhD**

ARP Research Methodology

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Wellsandt, Elizabeth, PhD, DPT**

ARP Orthopedics, Low Back Pain and Rehabilitation

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**White, Patience, MD, MA, MACR**

Patient Outcomes, Preferences, and Attitudes Category

Role: Abstract Reviewer

Disclosure: Pfizer, Stock (Ongoing)

**White, Daniel, PT, ScD**

ARP Psychology/Social Sciences

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Whitfield, Michael, PhD**

Systemic Sclerosis and Related Disorders: Basic Science Category

Role: Abstract Reviewer

Disclosure: No relevant disclosure to display

**Widdifield, Jessica, PhD**

ARP Health Services Research

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose



**Wilfong, Erin, MD, PhD**

Muscle Biology, Myositis and Myopathies – Basic and Clinical Science Category

Role: Abstract Chair

Disclosure: No relevant disclosure to display

**Wither, Joan, MD, PhD**

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Category

Role: Abstract Reviewer

Disclosure: AstraZeneca, 1 (Ongoing); Pfizer, Indirect salary support through a Chair award to the Division of Rheumatology at the University of Toronto (Terminated, June 30, 2022)

**Wright, Tracey, MD**

Systemic Lupus Erythematosus: Diagnosis, Manifestions, and Outcomes Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Wysham, Katherine, MD**

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**York, Michael, MD**

Health Services Research Category

Role: Abstract Chair

Disclosure: No financial relationships with ineligible companies to disclose

**Young, Kendra, PhD, MSPH**

ARP Epidemiology and Public Health Category

Role: Abstract Reviewer

Disclosure: No financial relationships with ineligible companies to disclose

**Young-Glazer, Jennifer, MD, MSCI**

Infection-related Rheumatic Disease Category

Role: Abstract Chair

Disclosure: ARGENX, Sub-PI on Clinical Trial (Ongoing)